Company Overview - The company, Disc, focuses on controlling red blood cell biology by managing the metabolism of iron and heme, which are essential for red blood cell formation [2] - The lead program, Bitopertin, is in-licensed from Roche and aims to control heme biosynthesis in red blood cells [2] Key Programs - Bitopertin is being studied for a rare disease called erythropoietic protoporphyria (EPP), with approximately 14,000 diagnosed patients in the U.S. [2] - The company has completed a Phase II program for Bitopertin and is currently in an accelerated approval process with the FDA [2] - The approval process was further expedited by receiving a Commissioner's National Priority Voucher [2]